New high purity resin advances bioprocessing and brings choice
and efficiencies to mAbs production workflow processes and
protocols
Monoclonal antibody drugs treat a wide variety of clinical
indications – for cancer treatments, mAbs enlist natural immune
system functions to fight the disease
RADNOR, Pennsylvania,
March 18, 2020 /PRNewswire/ --
Avantor, Inc. (NYSE: AVTR), a leading global provider of
mission-critical products and services to customers in the life
sciences, advanced technologies and applied materials industries,
today announced a new recombinant Protein A affinity chromatography
resin used to purify antibodies during mAbs production.
Healthcare demand is increasing rapidly across most of the
world, driven principally by aging populations, an increased
prevalence of chronic diseases and improved access to healthcare.
Monoclonal antibodies (mAbs) are proteins engineered to mimic or
enhance the body's immune system. Biopharmaceutical manufacturers
are pursuing ways to optimize the mAbs production process for
increased efficiency, speed-to-market and cost reduction.
Protein A chromatography is a proven downstream purification
step in manufacturing mAbs. Yet, there remains a need to reduce the
total purification costs while improving purity and yield. The new
Avantor® recombinant protein A resin addresses these
challenges.
Dr. Ger Brophy, Executive Vice
President for Biopharma Production at Avantor, said,
"Biopharmaceutical developers and manufacturers are urgently
seeking new tools to drive more efficiency in their production
processes. But they cannot compromise on quality standards as
they work to provide powerful medicines to patients in a timely,
safe and efficient manner."
In performance tests conducted against other best-in-class
Protein A resins on the market today, Avantor's novel
J.T.Baker® BAKERBOND® PROchievA™ recombinant
protein A resin demonstrated high performance and provided
best-in-class purification in the critical Protein A affinity
chromatography step of mAbs manufacturing. Avantor's resin is
compatible with current manufacturing standards which ensures
continuity in workflow processes and compliance protocols.
"Our resin provides customers with a best-in-class,
high-performing alternative to existing purification technology,
with the benefit of greater supply chain flexibility and security,"
added Dr. Brophy.
The BAKERBOND® PROchievA™ resin is manufactured at
Avantor's Bridgewater Innovation Center in N.J., USA and is the
company's latest example of driving improved bioprocessing
efficiencies for the Life Sciences industry. Avantor recently
teamed up with the National Institute for Bioprocessing Research
and Training (NIBRT) in Dublin,
Ireland to address downstream bottlenecks in buffer
preparation when producing mAbs. More recently Avantor opened its
ninth Innovation and Customer Support Center, which is located in
Shanghai, China.
The new resin enhances Avantor's J.T.Baker® family of
products for biopharmaceutical research and production. Avantor's
J.T.Baker® brand chromatography products allow biopharma
manufacturers to realize higher production efficiencies, meet
stringent regulatory requirements and accelerate regulatory
approval in bringing new therapies to market.
For more information about the BAKERBOND® PROchievA™
resin and other J.T.Baker® chromatography products,
visit www2.avantorsciences.com/ProteinA.
For information about Avantor's biopharma capabilities in
monoclonal antibodies, recombinant proteins, vaccines, cell and
gene therapies and small molecule products, visit
www.avantorsciences.com/en/biopharma.html.
About Avantor
Avantor® is a leading global provider of
mission-critical products and services to customers in the life
sciences, advanced technologies and applied materials industries.
The company operates in more than 30 countries and delivers an
extensive portfolio of products and services. As our channel brand,
VWR offers an integrated, seamless purchasing experience that is
optimized for the way our customers do business. We set science in
motion to create a better world. For information, visit
www.avantorsciences.com.
Global Media Contact
Robert Donohoe
Senior Director, Corporate Communications
Avantor
Office: 610-386-6420
Mobile: 484-688-4730
Robert.Donohoe@avantorsciences.com
Photo -
https://mma.prnewswire.com/media/1122321/Avantor_Protein_A_PROchievA.jpg
Logo - https://mma.prnewswire.com/media/718849/avantor_Logo.jpg